Natural history models for hepatitis C-related liver disease: Different disease progression parameters for different settings

Antiviral Therapy

Volumn 8, Issue 5, 2003, Pages 365-372

  Dore, Gregory J ^a   Freeman, Anthony J ^a   Law, Matthew ^a   Kaldor, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER DISEASE; MODEL; NONHUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; MARKOV CHAINS; MODELS, BIOLOGICAL;

EID: 0242331670     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG & Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine 1997; 127:855-865.
2. Wong JB, Bennett WG, Koff RS & Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. Journal of the American Medical Association 1998; 280:2088-2093.
3. Wong JB, McQuillan GM, McHutchison JG & Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 2000; 90:1562-1569.
4. Wong JB & Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Annals of Internal Medicine 2000; 133:665-675.
5. Sagmeister M, Renner EL, Mullhaupt B & Wong JB. Simulation of hepatitis C based on a mandatory reporting system. European Journal of Gastroenterology & Hepatology 2002; 14:25-34.
6. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG & Wong JB. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
7. Stein K, Rosenberg W & Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50:253-258.
8. Deuffic S, Buffat L, Poynard T & Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29:1596-1601.
9. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G & Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-816.
10. Nagelkerke NJ, Plummer FA, Holton D, Anzala AO, Manji F, Ngugi EN & Moses S. Transition dynamics of HIV disease in a cohort of African prostitutes: a Markov model approach. AIDS 1990; 4:743-747.
11. Wolfson C & Confavreux C. Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis. Neuroepidemiology 1987; 6:101-115.
12. Cowen ME, Chartrand M & Weitzel WF. A Markov model of the natural history of prostate cancer. Journal of Clinical Epidemiology 1994; 47:3-21.
13. Mattsson L, Weiland O & Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver 1988; 8:184-188.
14. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML & Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. Journal of Hepatology 1992; 16:273-281.
15. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastro-enterologica Belgica 1998; 61:238-242.
16. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J & Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. Journal of Hepatology 2001; 34:730-739.
17. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW & Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
18. Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M & Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17:783-784.
19. Gordon SC, Bayati N & Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28:562-567.
20. Hu KQ & Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-1316.
21. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E & Liddle C. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31:513-520.
22. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE & Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-1440.
23. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H & Tsuji T. Natural course of chronic hepatitis C. American Journal of Gastroenterology 1993; 88:240-243.
24. Yousuf M, Nakano Y, Tanaka E, Sodeyama T & Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scandinavian Journal of Gastroenterology 1992; 27:812-816.
25. Law MG. Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group. Journal of Gastroenterology & Hepatology 1999; 14:1100-1107.
26. Wasley A & Alter MJ. Epidemiology of hepatitis C: geographic differences and tempora trends. Seminars in Liver Diseases 2000; 20:1-16.
27. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J & Wodak A. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology 2003; (In Press).
28. Foster GR, Goldin RD & Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212.
29. NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2002. Sydney: National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales, 2002.
30. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C & Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
31. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S & Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine 1998; 339:1485-1492.
32. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H & Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Annals of Internal Medicine 2000; 132:517-524.
33. Dore GJ, Freeman A, Law M & Kaldor JM. Longitudinal studies of HCV-related liver disease progression: a systematic review and natural history model. 11th International Symposium on Viral Hepatitis & Liver Disease. Sydney, Australia, 6-10 April 2003.
34. Leroy V, De Traversay C, Barnoud R, Hartmann JD, Baud M, Ouzan D & Zarski JP. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. Journal of Hepatology 2001; 35:120-126.
35. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C & Pol S. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Human Pathology 2001; 32:904-909.
36. Wali M, Lewis S, Hubscher S, Harrison R, Ahmed M, Elias E & Mutimer D. Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 1999; 6:445-452.
37. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P & Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116:378-386.
38. Freeman AJ, Law MG, Kaldor IM & Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis 2003; 10:285-293.
39. Lauer GM & Walker BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345:41-52.
40. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P & Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-1137.
41. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C & Poynard T, The Multivir C Group. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.